SLC5A2 and hypertensive nephropathy: Compared with the non-sodium-glucose cotransporter-2 inhibitor (SGLT2i) group, the SGLT2i group demonstrated a 59% reduction in creatinine, while the diabetic subgroup showed a 47.1% smaller reduction than the nondiabetic subgroup.<h4>Conclusions</h4>Bosentan may improve glomerular haemodynamics in patients with hypertensive nephropathy.